Do you want to read an article? Please log in or register.
What is the Optimal Dose and Fractionation Schedule for Inoperable Node-Negative Large (≥ 5 cm) Non-Small Cell Lung Cancer?
Lung Cancer
Related content
Lung Cancer
Combined Impact of Coronary Artery Calcification and Heart Radiation Dose on Overall Survival in Locally Advanced Non-Small Cell Lung Cancer: Who Benefits Most from Reducing Heart Radiation Dose?
Clin Lung Cancer
Watanabe Y, Koide Y, Shimizu H, Aoyama T, Shindo Y, Hashimoto S, Tachibana H, Kodaira T
doi: 10.1016/j.cllc.2025.05.002
Lung Cancer
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
Lung Cancer
Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T
doi: 10.1016/j.lungcan.2025.108671
Lung Cancer
Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
Clin Lung Cancer
Zhu Z, Wu J, Zhao L, Jiang N, Chen Y, Song X, Li M, Jiang M, Shi M, Yu S, Ren B, Yin R, Jiang F, Wang L, Kong C, Zhu X
doi: 10.1016/j.cllc.2025.01.012
Lung Cancer
Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients
Clin Lung Cancer
Verschueren MV, Hiensch DTA, Plomp PMJ, Kastelijn LA, van de Garde EMW, Peters BJM
doi: 10.1016/j.cllc.2025.01.009
Lung Cancer
MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review
Lung Cancer
Shi Y, Chen R, Xiong Y, Geng R, Guo C, Liu L, Chen Y, Wang Y
doi: 10.1016/j.lungcan.2025.108634
Lung Cancer
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study
Clin Lung Cancer
Koster KL, Yohasenan S, Pakmak AS, Mark M, Metaxas Y, Lips C, Hitz F, Leskow P, Ludwig C, Putora PM, Glatzer M, Schneider T, Caviezel C, Mader T, Mousavi M, Blum M, Früh M, Joerger M
doi: 10.1016/j.cllc.2025.05.010
RECOMMENDED
Lung Cancer
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Barrichello APC, Elkrief A, Ricciuti B, Ganta T, Marron TU, Wang X, Lotter W, Lindsay J, Santo V, Cortellini A, Sharma B, Felt K, Pfaff K, Lamberti G, Pecci F, Federico AD, Makarem M, Gandhi MM, Nguyen T, Haradon D, Vaz VR, Johnson BE, Debnath N, Wang Y, Kuang AG, Saeed A, Radford M, Lovly CM, Nebhan CA, Pinato DJ, Rodig SJ, Schoenfeld AJ, Awad MM, Alessi JV, Naqash AR
doi: 10.1016/j.cllc.2025.01.014
Lung Cancer
Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study
Sci Rep
Wang L, Wang R, Wei Z, Wang Y, Chen H, Dong B, Hu X, Ma H, Wang Z, Feng W, Li P, Lin X, Xu Y
doi: 10.1038/s41598-024-73177-2
Lung CancerFurther Publications
Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
Respir Med Case Rep
Sakakibara-Konishi J, Takahashi H, Ito K, Ikari T, Ikezawa Y, Kitai H, Furuta M, Takashima Y, Shoji T, Fukudo M, Konno S
doi: 10.1016/j.rmcr.2025.102176